Novartis AG — Director's Dealing 2016

Oct 26, 2016

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Ra Pharmaceuticals, Inc. (RARX)
CIK: 0001481512
Period of Report: 2016-10-25

Reporting Person: Novartis Bioventures Ltd (10% Owner)
Reporting Person: NOVARTIS AG (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Warrants to Purchase Common Stock	$0.07	2022-04-01	Common Stock (62575)		Direct
Series A Preferred Stock	$		Common Stock (1389797)		Direct
Series B-1 Preferred Stock	$		Common Stock (522561)		Direct
Series B-2 Preferred Stock	$		Common Stock (486104)		Direct

Footnotes

F1: The board of directors of Novartis Bioventures Ltd. has sole voting and investment control and power over such securities. None of the members of its board of directors has individual voting or investment power with respect to such securities and each disclaims beneficial ownership of such securities. Novartis Bioventures Ltd. is an indirectly owned subsidiary of Novartis AG.

F2: The Warrants to Purchase Common Stock have a $0.07 exercise price and are automatically exercised for shares of Common Stock on a net issuance basis upon consummation of the Issuer's initial public offering of Common Stock.

F3: Each share of the Series A Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.

F4: Each share of the Series B-1 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.

F5: Each share of the Series B-2 Preferred Stock is convertible into Common Stock on a 1-for-7 basis automatically upon the closing of the Issuer's initial public offering, and has no expiration date.